17,261 trials
Diabetic Retinopathy
Primary: Single-rising Dose (SRD) Part - The Number of Patients With Dose Limiting Events (DLEs) From Drug Administration Until Day 8 — 0; 0; 0 Participants
Norovirus Infections
Primary: Viral-capsid Protein 1 (VP1)-Specific Antibody Secreting Cells (ASC) by Enzyme-linked Immunospot (ELISpot) Assay — 1.3; 0.5; 0.3; 127.6 Spot Forming Units per 10^6 PBMC
Myelodysplastic Syndromes (MDS) · Acute Myelogenous Leukemia (AML)
Primary: Relapse Rate — 20; 2; 10 Participants
Idiopathic Pulmonary Fibrosis (IPF)
Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) — -316.60; -127.41 mL/Year
Breast Cancer
Primary: Objective Response Rate Per Composite Response Criteria — 7.5; 48.6; 33.3 percent of participants
Malaria
Primary: Incidence of Clinical Malaria Meeting the Primary Case Definition — 0.45; 0.36 events per person-year — p=0.154
Esophageal Spasm
Primary: Esophageal Symptoms Questionnaire Score (ESQ) — 24; 35 score on a scale
Glioblastoma Multiforme
Primary: 6-month Progression-free Survival (PFS) — 1 Participants
Thyroid Cancer
Primary: Best Overall Response Rate — 9.4; 0; 30 percentage of participants
Liver Metastases · Lung Metastases · Recurrent Melanoma
Primary: Rate of Progression-free Survival by mWHO Criteria — 0.75 months
Concussion, Brain · Traumatic Brain Injury
Primary: Symptom Management - Post Concussion Symptom Scale — 44; 71; 39; 51 score on a scale
Refractory Follicular Lymphoma · Relapsed Follicular Lymphoma
Primary: Recommended Phase 2 Dose (RP2D) — 0; 1; 0; 0 Dose Limiting toxicities
Von-Hippel Lindau · Kidney Disease, Chronic
Primary: Comparison in Radiologist's Lesion Evaluation: CEUS Versus B-mode Ultrasound — 0.13; 0.20 Dichotomized score
Diabetic Foot Ulcer
Primary: Safety Outcome — 1; 3; 9; 6 Participants
Shigella
Primary: Number of Participants With Moderate-Severe Shigellosis Illness, With Challenge — 14; 17 Participants